ID1 expression was found to be on average 2.5-fold higher (and up to 5.4-fold higher) in CD11B+ PBMCs from patients with metastatic melanoma (n=15) compared with healthy, age-matched controls (n=7, unpaired t-test, P<0.05; Fig. 7a). The gene discussed is ID1; the disease is metastatic melanoma.